Advertisement

Springer Nature is making SARS-CoV-2 and COVID-19 research free. View research | View latest news | Sign up for updates

Infliximab may be cost effective in severe, treatment-resistant RA

    This is a preview of subscription content, log in to check access.

    Rights and permissions

    Reprints and Permissions

    About this article

    Cite this article

    Infliximab may be cost effective in severe, treatment-resistant RA. Pharmacoecon. Outcomes News 480, 9 (2005). https://doi.org/10.2165/00151234-200504800-00025

    Download citation

    Keywords

    • Rheumatoid Arthritis
    • Methotrexate
    • Infliximab
    • Incremental Cost
    • Medical Information System